BY

Park Ha Biological Technology Co., Ltd.

BYAHConsumer DefensiveNASDAQ

Household & Personal Products · Last scanned Jul 22, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.5M
+6.0% YoY
Net Income
-$24.4M
-5191.3% YoY
EBITDA
-$24.0M
-3037.7% YoY
Free Cash Flow
$9.9M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 RSI OversoldRSI 5.2, below 30, stock may be oversold
Jul 14 RSI OversoldRSI 8.2, below 30, stock may be oversold
About Park Ha Biological Technology Co., Ltd.

Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. Valued at $3.3M, BYAH is a micro-cap name in its sector. It operates in two segments, Product Sales and Franchise Service.

Where BYAH stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, BYAH finished 87.84% below its 150-day moving average ($3.29) and 94.23% below its 200-day moving average ($6.93). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is BYAH overbought or oversold?

At the July 15, 2026 close, BYAH's RSI(14) was 5.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$3.3M
EPS$-2181.17
52W Change-98.8%
ROE-885.8%
Analysis

The balance sheet looks solid with $3.8M in cash comfortably exceeding the $180K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $9.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -885.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.9M (2022) to $2.5M (2025), reflecting a 32% increase over the period.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Park Ha Biological Technology Co., Ltd. and its sector.

Links
More Consumer Defensive stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
BYAH: Park Ha Biological Technology Co., Ltd. Technical Analysis (200-Day MA, RSI, MACD) | Scanance